Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Many Bright Ideas TechnologiesMBGNF Return-on-Tangible-Equity is 0.00% as of Mar. 2026. The stock has 1 warning sign investors should review. Among 192 Medical Diagnostics & Research companies, Many Bright Ideas Technologies ranks worse than 520832.81% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Many Bright Ideas Technologies's annualized net income for the quarter that ended in Mar. 2026 was $-0.04 Mil. Many Bright Ideas Technologies's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $-0.23 Mil. Therefore, Many Bright Ideas Technologies's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was N/A%.
The historical rank and industry rank for Many Bright Ideas Technologies's Return-on-Tangible-Equity or its related term are showing as below:
MBGNF's Return-on-Tangible-Equity is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -0.605 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Many Bright Ideas Technologies (OTCPK:MBGNF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Many Bright Ideas Technologies Return-on-Tangible-Equity Related Terms
Many Bright Ideas Technologies Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Many Bright Ideas Technologies Return-on-Tangible-Equity Chart
MBGNF vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Many Bright Ideas Technologies's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Many Bright Ideas Technologies Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Many Bright Ideas Technologies's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Many Bright Ideas Technologies's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.00% mean?
Many Bright Ideas Technologies (MBGNF) has a Return-on-Tangible-Equity of 0.00% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Many Bright Ideas Technologies and its competitors. According to the industry distribution chart, Many Bright Ideas Technologies ranks #999999 out of 192 companies in the Medical Diagnostics & Research industry.
Is Many Bright Ideas Technologies' Return-on-Tangible-Equity too high?
Many Bright Ideas Technologies' current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, Many Bright Ideas Technologies ranks #999999 out of 192 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Many Bright Ideas Technologies' Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Many Bright Ideas Technologies ranks #999999 out of 192 companies for Return-on-Tangible-Equity. This places Many Bright Ideas Technologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Equity depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Many Bright Ideas Technologies and its competitors. Many Bright Ideas Technologies's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Many Bright Ideas Technologies stock overvalued right now?
Many Bright Ideas Technologies (MBGNF) has a current Return-on-Tangible-Equity of 0.00%. The current Return-on-Tangible-Equity is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Many Bright Ideas Technologies (MBGNF), the current Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Many Bright Ideas Technologies Business Description
Many Bright Ideas Technologies Inc is a Canada-based life science company. It focused on the development and commercialization of genomic-based clinical laboratory diagnostic tests. The company is engaged in managing the license and rights to GeneFx Lung, which is a proprietary gene expression-based test for identifying those patients with early-stage non-small-cell lung cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBGNF has been successfully added to your 
